The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Burleva E.P.

Kafedra obshcheĭ khirurgii GOU VPO "Ural'skaia gosudarstvennaia meditsinskaia akademiia", Ekaterinburg

Kremenevskiy O.M.

Road Clinical Hospital at the Ekaterinburg-Passazhirskiy station of Russian Railways, Ekaterinburg, Russia

Prolonged Anticoagulation Therapy for venous Thromboembolism: Resolved Issuesand Controversial Questions

Authors:

Burleva E.P., Kremenevskiy O.M.

More about the authors

Journal: Journal of Venous Disorders. 2019;13(1): 42‑51

DOI: 10.17116/flebo20191301142

Read: 2772 times

Download PDF (RU)
Contact the author
Table of contents

PROLONGED ANTICOAGULATION THERAPY FOR VENOUS THROMBOEMBOLISM: RESOLVED ISSUESAND CONTROVERSIAL QUESTIONS
PROLONGED ANTICOAGULATION THERAPY FOR VENOUS THROMBOEMBOLISM: RESOLVED ISSUESAND CONTROVERSIAL QUESTIONS

To cite this article:

Burleva EP, Kremenevskiy OM. Prolonged Anticoagulation Therapy for venous Thromboembolism: Resolved Issuesand Controversial Questions. Journal of Venous Disorders. 2019;13(1):42‑51. (In Russ.)
https://doi.org/10.17116/flebo20191301142

 
Подписка 2026 Флебология (Journal of Venous Disorders)
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Posi­tive Predictive Value of the Wells Score in Diagnosis of Deep Vein Thro­mbosis: Resu­lts of Bayesian Analysis. Journal of Venous Diso­rders. 2024;(4):274-282
Comparison of prognostic scales of myasthenic crisis after thymectomy in patients with myasthenia gravis. Russian Journal of Anesthesiology and Reanimatology. 2024;(6):63-69
Abstract:

The article is devoted to the most controversial issue of the treatment of venous thromboembolic complications (VTEC associated with deep vein thrombosis and pulmonary embolism) — prolonged anticoagulation therapy (ACT) and includes reports which have been published over the last 2 decades. It is emphasized that outpatient physician resolves some difficult issues related to ACT prolongation. Therefore, it is particularly important to develop clear, precise and acceptable for the practice schemes of ACT prolongation in certain groups of patients. The risks of recurrent thrombosis and bleeding should be considered if ACT is prolonged in VTEC patients. This review includes some trials reporting advanced risks of recurrent VTEC after ACT discontinuation. High-risk groups of patients are especially outlined. These are patients with idiopathic thrombosis, genetic and acquired thrombophilia, malignancies, cava-filters. Predictive role of increased level of D-dimer and residual venous stenosis for recurrent VTEC is discussed. Prognostic scales for assessing the risk of recurrent venous thrombosis are given. The second part of the review is devoted to the risks of bleeding on the background of prolonged ACT. The data of some metaanalyses devoted to gastrointestinal and intracranial hemorrhage in patients receiving oral anticoagulants and antiplatelet drugs are presented. Prognostic scales for assessing the risk of bleeding on the background of anticoagulant therapy are given.

Keywords:

venous thromboembolic complications
prolonged anticoagulation therapy
risks of recurrent thrombosis
risks of bleeding
prognostic scales
direct oral anticoagulants

Authors:

Burleva E.P.

Kafedra obshcheĭ khirurgii GOU VPO "Ural'skaia gosudarstvennaia meditsinskaia akademiia", Ekaterinburg

Kremenevskiy O.M.

Road Clinical Hospital at the Ekaterinburg-Passazhirskiy station of Russian Railways, Ekaterinburg, Russia

Close metadata

References:

  1. Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, Nelson ME, Wells PS, Gould MK, Dentali F, Crowther M, Kahn SR. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Antithrombotic Therapy for VTE Disease. Chest. 2012;142(6):1698-1704.
  2. Russian clinical recommendations for diagnosis, treatment and prevention of venous thromboembolic complications. Flebologiya. 2015;9(4):52. (In Russ.)
  3. Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008 Jun;133 (6 Suppl):454S-545S. https://doi.org/10.1378/chest.08-0658
  4. Prandoni P, Noventa F, Ghirarduzzi A, Pengo V, Bernardi E, Pesavento R, Iotti M, Tormene D, Simioni P, Pagnan A. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica. 2007 Feb;92(2):199-205.
  5. Spencer FA, Emery C, Joffe SW, Pacifico L, Lessard D, Reed G, Gore JM, Goldberg RJ. Incidence rates, clinical profile, and outcomes of patients with venous thromboembolism. The Worcester VTE Study. J Thromb Thrombolysis. 2009;28(4):401-409. https://doi.org/10.1007/s11239-009-0378-3
  6. Huang W, Goldberg RJ, Anderson FA, Kiefe CI, Spencer FA. Secular trends in occurrence of acute venous thromboembolism: the Worcester VTE study (1985—2009). Am J Med. 2014;127:829.e5-839.e5. https://doi.org/10.1016/j.amjmed.2014.03.041
  7. Baglin T, Luddington R, Brown K, Baglin C. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet. 2003;362:523-526.
  8. Iorio A, Kearon C, Filippucci E, Marcucci M, Macura A, Pengo V, Siragusa S, Palareti G. Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review. Arch Intern Med. 2010;170(19):1710-1171. https://doi.org/10.1001/archinternmed.2010.367
  9. Kovacs MJ, Kahn SR, Wells PS, Anderson DA, Chagnon I, LE Gal G, Solymoss S, Crowther M, Perrier A, Ramsay T, Betancourt MT, White RH, Vickars L, Rodger MA. Patients with a first symptomatic unprovoked deep vein thrombosis are at higher risk of recurrent venous thromboembolism than patients with a first unprovoked pulmonary embolism. J Thromb Haemost. 2010;8(9):1926-1932. https://doi.org/10.1111/j.1538-7836.2010.03958.x
  10. Kyrle PA, Minar E, Bialonczyk C, Hirschl M, Weltermann A, Eichinger S. The risk of recurrent venous thromboembolism in men and women. N Engl J Med. 2004;350(25):2558-2563. https://doi.org/10.1056/NEJMoa032959
  11. Eichinger S, Heinze G, Jandeck LM, Kyrle PA. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model. Circulation. 2010;121(14):1630-1636. https://doi.org/10.1161/CIRCULATIONAHA.109.925214
  12. Tosetto A, Iorio A, Marcucci M, Baglin T, Cushman M, Eichinger S, Palareti G, Poli D, Tait RC, Douketis J. Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH). J Thromb Haemost. 2012;10(6):1019-1025. https://doi.org/10.1111/j.1538-7836.2012.04735.x
  13. Spencer FA, Emery C, Joffe SW, Pacifico L, Lessard D, Reed G, Gore JM, Goldberg RJ. Incidence rates, clinical profile, and outcomes of patients with venous thromboembolism. The Worcester VTE Study. J Thromb Thrombolysis. 2009;28(4):401-409. https://doi.org/10.1007/s11239-009-0378-3
  14. Baglin T, Douketis J, Tosetto A, Marcucci M, Cushman M, Kyrle P, Palareti G, Poli D, Tait RC, Iorio A. Does the clinical presentation and extent of venous thrombosis predict likelihood and type of recurrence? A patient-level metaanalysis. J Thromb Haemost. 2010;8(11):2436-2442. https://doi.org/10.1111/j.1538-7836.2010.04022.x
  15. Boutitie F, Pinede L, Schulman S, Agnelli G. Raskob G, Julian J, Hirsh J, Kearon C. Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants’ data from seven trials. BMJ. 2011;342:d3036. d https://doi.org/10.1136/bmj.d3036
  16. Garcia D, Akl EA, Carr R, Kearon C. Antiphospholipid antibodies and the risk of recurrence after a first episode of venous thromboembolism: a systematic review. Blood. 2013;122(5):817-824. https://doi.org/10.1182/blood-2013-04-496257
  17. Jayakody Arachchillage D, Greaves M. The chequered history of the antiphospholipid syndrome. Br J Haematol. 2014;165(5):609-617. https://doi.org/10.1111/bjh.12848
  18. Vossen CY, Conard J, Fontcuberta J, Macris M, van der Meer FJM, Pabinger I, Palareti G, Preston FE, Scharrer I, Souto JC, Svensson P, Walker ID, Rosendaal FR. Risk of a first venous thrombotic event in carriers of a familial thrombophilic defect. The European Prospective Cohort on Thrombophilia (EPCOT). J Thromb Haemost. 2005;3(3):459-464. https://doi.org/10.1111/j.1538-7836.2005.01197.x
  19. Mahmoodi BK, Brouwer JL, Ten Kate MK, Lijfering WM, Veeger NJ, Mulder AB, Kluin-Nelemans HC, Van Der Meer J. A prospective cohort study on the absolute risks of venous thromboembolism and predictive value of screening asymptomatic relatives of patients with hereditary deficiencies of protein S, protein C or antithrombin. J Thromb Haemost. 2010;8(6):1193-1200. https://doi.org/10.1111/j.1538-7836.2010.03840.x
  20. Brouwer JL, Lijfering WM, Ten Kate MK, Kluin-Nelemans HC, Veeger NJ, van der Meer J. High long-term absolute risk of recurrent venous thromboembolism in patients with hereditary deficiencies of protein S, protein C or antithrombin. Thromb Haemost. 2009;101(1):93-99.
  21. Wells PS, Forgie MA, Rodger MA. Treatment of venous thromboembolism. JAMA. 2014;311:717-728. https://doi.org/10.1001/jama.2014.65
  22. Ho WK, Hankey GJ, Quinlan DJ, Eikelboom JW. Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review. Arch Intern Med. 2006;166(7):729-736. https://doi.org/10.1001/archinte.166.7.729
  23. Verhovsek M, Douketis JD, Yi Q, Shrivastava S, Tait RC, Baglin T, Poli D, Lim W. Systematic review: D-dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism. Ann Intern Med. 2008;149(7):481-490.
  24. Cosmi B, Legnani C, Tosetto A, Pengo V, Ghirarduzzi A, Testa S, Prisco D, Poli D, Tripodi A, Marongiu F, Palareti G. Usefulness of repeated D-dimer testing after stopping anticoagulation for a first episode of unprovoked venous thromboembolism: the PROLONG II prospective study. Blood. 2010;115(3):481-488.
  25. Palareti G, Cosmi B, Legnani C, Antonucci E, De Micheli V, Ghirarduzzi A, Poli D, Testa S, Tosetto A, Pengo V, Prandoni P; DULCIS (D-dimer and ULtrasonography in Combination Italian Study) Investigators. D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism: a management study. Blood. 2014124(2):196-203. https://doi.org/10.1182/blood-2014-01-548065
  26. Prandoni P, Lensing AW, Prins MH, Bernardi E, Marchiori A, Bagatella P, Frulla M, Mosena L, Tormene D, Piccioli A, Simioni P, Girolami A. Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Ann Intern Med. 2002;137(12)955-960.
  27. Schulman S, Lindmarker P, Holmström M, Laärfars G, Carlsson A, Nicol P, Svensson E, Ljungberg B, Viering S, Nordlander S, Leijd B, Jahed K, Hjorth M, Linder O, Beckman M. Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months. J Thromb Haemost. 2006;4:734-742.
  28. Tan M, Mos IC, Klok FA, Huisman MV. Residual venous thrombosis as predictive factor for recurrent venous thromboembolim in patients with proximal deep vein thrombosis: a sytematic review. Br J Haematol. 2011;153(2):168-178. https://doi.org/10.1111/j.1365-2141.2011.08578.x
  29. Cosmi B, Legnani C, Iorio A, Pengo V, Ghirarduzzi A, Testa S, Poli D, Tripodi A, Palareti G; PROLONG Investigators (on behalf of FCSA, Italian Federation of Anticoagulation Clinics). Residual venous obstruction, alone and in combination with D-dimer, as a risk factor for recurrence after anticoagulation withdrawal following a first idiopathic deep vein thrombosis in the prolong study. Eur J Vasc Endovasc Surg. 2010;39(3):356-365. https://doi.org/10.1016/j.ejvs.2009.11.022
  30. Carrier M, Rodger MA, Wells PS, Righini M, LE Gal G. Residual vein obstruction to predict the risk of recurrent venous thromboembolism in patients with deep vein thrombosis: a systematic review and metaanalysis. J Thromb Haemost. 2011;9(6):1119-1125. https://doi.org/10.1111/j.1538-7836.2011.04254.x
  31. Donadini MP, Ageno W, Antonucci E, Cosmi B, Kovacs MJ, Le Gal G, Ockelford P, Poli D, Prandoni P, Rodger M, Saccullo G, Siragusa S, Young L, Bonzini M, Caprioli M, Dentali F, Iorio A, Douketis JD. Prognostic significance of residual venous obstruction in patients with treated unprovoked deep vein thrombosis: a patient-level metaanalysis. Thromb Haemost. 2014;111(1):172-179. https://doi.org/10.1160/TH13-04-0336
  32. Heit JA. Epidemiology of venous thromboembolism. Nat Rev Cardiol. 2015;12(8):464-474. https://doi.org/10.1038/nrcardio.2015.83
  33. Chee ChE, Ashrani AA, Marks RS, Petterson TM, Bailey KR, Heit JA. Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a population-based cohort study. Blood. 2014;19; 123(25):3972-3978. https://doi.org/10.1182/blood-2014-01-549733
  34. Prandoni P, Lensing AW, Piccioli A, Bernardi E, Simioni P, Girolami B, Marchiori A, Sabbion P, Prins MH, Noventa F, Girolami A. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002;100(10):3484-3488. https://doi.org/10.1182/blood-2002-01-0108
  35. Louzada ML, Carrier M, Lazo-Langner A, Dao V, Kovacs MJ, Ramsay TO, Rodger MA, Zhang J, Lee AY, Meyer G, Wells PS. Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism. Circulation. 2012;126 (4):448-454. https://doi.org/10.1161/CIRCULATIONAHA.111.051920
  36. Schulman S, Zondag M, Linkins L, Pasca S, Cheung YW, de Sancho M, Gallus A, Lecumberri R, Molnar S, Ageno W, Le Gal G, Falanga A, Hulegårdh E, Ranta S, Kamphuisen P, Debourdeau P, Rigamonti V, Ortel TL, Lee A. Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis. J Thromb Haemost. 2015 Jun;13(6):1010-1018. https://doi.org/10.1111/jth.12955
  37. Yale SH, Mazza JJ, Glurich I, Peters T, Mukesh BN. Recurrent venous thromboembolism in patients with and without anticoagulation after inferior vena caval filter placement. Int Angiol. 2006;25(1):60-66.
  38. Patel SH, Patel R. Inferior Vena Cava Filters for Recurrent Thrombosis. Current Evidence Tex Heart Inst J. 2007;34(2):187-194.
  39. Molvar C. Inferior Vena Cava Filtration in the Management of Venous Thromboembolism: Filtering the Data. Semin Intervent Radiol. 2012;29(3):204-217. https://doi.org/10.1055/s-0032-1326931
  40. Coombs C, Kuk D, Devlin S, Siegelbaum RH, Durack JC, Parameswaran R, Mantha S, Deng K, Soff G. Outcomes after inferior vena cava filter placement in cancer patients diagnosed with pulmonary embolism: risk for recurrent venous thromboembolism. J Thromb Thrombolysis. 2017;44(4):489-493. https://doi.org/10.1007/s11239-017-1557-2
  41. Barnes GD, Kanthi Y, Froehlich JB. Venous thromboembolism: Predicting recurrence and the need for extended anticoagulation. Vasc Med. 2015;20(2):143-152. https://doi.org/10.1177/1358863X14566429
  42. Eichinger S, Heinze G, Jandeck LM., et al. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model. Circulation. 2010;121:1630-1636. https://doi.org/10.1161/CIRCULATIONAHA.109.925214
  43. Kearon C, Akl EA, Ornelas J, Blaivas A, Bounameaux H, Huisman M, Morris TA, Sood N., Stevens SM, Vintch JRE, Wells P, Woller SC, Moores L. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest. 2016;149(2):315-335. https://doi.org/10.1016/j.chest.2015.11.026
  44. Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med. 2011; 24;365(21):2002-2012. https://doi.org/10.1056/NEJMsa1103053
  45. Linkins LA, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a metaanalysis. Ann Intern Med. 2003;2:139(11):893-900.
  46. Castellucci LA, Cameron C, Le Gal G, Rodger MA, Coyle D, Wells PS, Clifford T, Gandara E, Wells G, Carrier M Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network metaanalysis. BMJ. 2013;30;347:f5133. https://doi.org/10.1136/bmj.f5133
  47. Flaherty ML, Kissela B, Woo D, Kleindorfer D, Alwell K, Sekar P, Moomaw CJ, Haverbusch M, Broderick JP. The increasing incidence of anticoagulant-associated intracerebral hemorrhage. Neurology. 2007;68(2):116-121. https://doi.org/10.1212/01.wnl.0000250340.05202.8b
  48. Goldstein JN, Greenberg SM. Should anticoagulation be resumed after intracerebral hemorrhage? Cleve Clin J Med. 2010 Nov;77(11):791-799. https://doi.org/10.3949/ccjm.77a.10018
  49. Huhtakangas J, Tetri S, Juvela S, Saloheimo P, Bode MK, Hillbom M. Effect of increased warfarin use on warfarin-related cerebral hemorrhage: a longitudinal population-based study. Stroke. 2011;42(9):2431-2435. https://doi.org/10.1161/STROKEAHA.111.615260
  50. Moustafa F, Pierfranceschi MG, Di Micco P, Bucherini E, Lorenzo A, Villalobos A, Nieto JA, Valero B, Sampériz ÁL, Monreal M, the RIETE Investigators. Clinical outcomes during anticoagulant therapy in fragile patients with venous thromboembolism. Res Pract Thromb Haemost. 2017;1(2):172-179. https://doi.org/10.1002/rth2.12036
  51. Donzé J, Rodondi N, Waeber G, Monney P, Cornuz J, Aujesky D. Scores to Predict Major Bleeding Risk During Oral Anticoagulation Therapy: A Prospective Validation Study. American J of Meditsine. 2012;125:1095-1102. https://doi.org/10.1016/j.amjmed.2012.04.005
  52. Ruiz-Gimenez N, Suarez C, Gonzalez R, et al. Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost. 2008;100:26-31. https://doi.org/10.1160/TH08-03-0193
  53. Simes J, Becattini C, Agnelli G, Eikelboom JW, Kirby AC, Mister R, Prandoni P, Brighton TA. Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration. Circulation. 201 ; 23;130(13):1062-1071. https://doi.org/10.1161/CIRCULATIONAHA.114.008828
  54. Huang ES, Strate LL, Ho WW, Lee SS, Chan AT. Long-Term Use of Aspirin and the Risk of Gastrointestinal Bleeding. Am J Med. 2011;124(5):426-433. https://doi.org/10.1016/j.amjmed.2010.12.022
  55. Oakland K, Desborough MJ, Murphy MF, Schachter M, Jairath V. Re-bleeding and Mortality After Lower Gastrointestinal Bleeding in Patients Taking Anti-platelets or Anti-coagulants. Clin Gastroenterol Hepatol. 2017;23. https://doi.org/10.1016/j.cgh.2017.12.032
  56. Bauer KA. Pros and cons of new oral anticoagulants. Hematology Am Soc Hematol Educ Program. 2013;2013:464-470. https://doi.org/10.1182/asheducation-2013.1.464
  57. Galanis T, Keiffer G, Merli G. The New Oral Anticoagulants for the Treatment of Venous Thromboembolism: A New Paradigm Shift in Antithrombotic Therapy. Curr Ther Res Clin Exp. 2014;76:76-83. https://doi.org/10.1016/j.curtheres.2014.06.002
  58. Yeh CH, Gross PL, Weitz JI. Evolving use of new oral anticoagulants for treatment of venous thromboembolism. Blood. 2014;124(7):1020-1028. https://doi.org/10.1182/blood-2014-03-563056
  59. Marik PE, Cavallazzi R. Extended Anticoagulant and Aspirin Treatment for the Secondary Prevention of Thromboembolic Disease: A Systematic Review and MetaAnalysis. PLoS One. 2015 20;10(11):e0143252. https://doi.org/10.1371/journal.pone.0143252
  60. Wu C, Alotaibi GS, Alsaleh K, McMurtry MS. Case fatality of bleeding and recurrent venous thromboembolism during, initial therapy with direct oral anticoagulants: a systematic review. Thromb Res. 2014;134(3):627-632. https://doi.org/10.1016/j.thromres.2014.07.001
  61. Wu C, Alotaibi GS, Alsaleh K, Linkins LA, McMurtry MS. Case-fatality of recurrent venous thromboembolism and major bleeding associated with aspirin, warfarin, and direct oral anticoagulants for secondary prevention. Thromb Res. 2015;135(2):243-248. https://doi.org/10.1016/j.thromres.2014.10.033
  62. Verso M, Agnelli G, Prandoni P. Pros and cons of new oral anticoagulants in the treatment of venous thromboembolism in patients with cancer. Intern Emerg Med. 2015;10(6):651-656. https://doi.org/10.1007/s11739-015-1233-5
  63. EINSTEIN Investigators, Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE,Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Davidson BL, Piovella F, Schellong S. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;23;363(26):2499-2510. https://doi.org/10.1056/NEJMoa1007903
  64. EINSTEIN-PE Investigators, Büller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, Chlumsky J, Verhamme P, Wells P, Agnelli G, Cohen A, Berkowitz SD, Bounameaux H, Davidson BL, Misselwitz F, Gallus AS, Raskob GE, Schellong S, Segers A. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366(14):1287-1297. https://doi.org/10.1056/NEJMoa1113572
  65. Prins MH, Lensing AWA, Bauersachs R, van Bellen B, Bounameaux H, Brighton TA, Cohen AT, Davidson BL, Decousus H, Raskob GE, Berkowitz SD, Wells PS. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thrombosis Journal. 2013;11:21-30. https://doi.org/10.1186/1477-9560-11-21
  66. Mantha S, Laube E, Miao Y, Sarasohn DM, Parameswaran R, Stefanik S, Brar G, Samedy P, Wills J, Harnicar S, Soff GA. Safe and effective use of rivaroxaban for treatment of cancer-associated venous thromboembolic disease: a prospective cohort study. J Thromb Thrombolysis. 2017;43(2):166-171. https://doi.org/10.1007/s11239-016-1429-1
  67. Romualdi E, Donadini1 MP, Ageno W. Oral rivaroxaban after symptomatic venous thromboembolism: the continued treatment study (EINSTEIN-Extension study). Expert Rev Cardiovasc Ther. 2011;9(7),841-844. https://doi.org/10.1586/erc.11.62
  68. Weitz JI, Lensing AWA, Prins MH, Bauersachs R, Beyer-Westendorf J, Bounameaux H, Brighton TA, Cohen AT, Davidson BL, Decousus H, Freitas MCS, Holberg G, Kakkar AK, Haskell L, van Bellen B, Pap AF, Berkowitz SD, Verhamme P, Wells PS, Prandoni P; EINSTEIN CHOICE Investigators. Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. N Engl J Med. 2017 30;376(13):1211-1222. https://doi.org/10.1056/NEJMoa1700518
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.